At Madrigal, we are committed to transforming treatment for patients with non-alcoholic steatohepatitis (NASH). NASH will soon become the leading cause of liver transplantation in the U.S., but there are currently no approved medications to treat the disease.

Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Positive results from first of the two Phase 3 clinical trials of resmetirom in NASH were announced in January 2022 and results from a second Phase 3 clinical trial are expected in Q4 2022. Resmetirom is on track to launch in the U.S. towards the end of 2023.

Madrigal has established its leadership position in NASH by staying true to its science-driven foundation and building a company culture based on collaboration and trust. Our team members are focused on delivering results for the benefit of investors, healthcare providers, and, most importantly, patients. These values will remain central to Madrigal as the company grows and evolves its commercial capabilities to prepare for a potential first-to-market launch in NASH.

The Madrigal Story:

 

2004-2008:Madrigal founder Dr. Rebecca Taub studies THR-B agonism while working at Hoffmann-La Roche

 

2008: Madrigal predecessor company VIA Pharmaceuticals hires Dr. Taub and enters into a development agreement with Hoffmann-La Roche for resmetirom

 

2011: Madrigal is incorporated in Delaware and Ph 1 trial of resmetirom commences

 

2016: Ph 2 trial of resmetirom in NASH commences; Madrigal merges with Synta Pharmaceuticals and is listed on NASDAQ; and Dr. Paul Friedman named CEO and Rebecca Taub named CMO of Madrigal

2017-2018: Positive Phase 2 results in NASH help accelerate Madrigal’s growth

2019: Madrigal commences Phase 3 “MAESTRO” program for resmetirom

2020: Madrigal hires Remy Sukhija as Chief Commercial Officer and begins building its commercial organization

2021: Madrigal continues to expand executive team

2021-2022: Positive Phase 3 MAESTRO-NAFLD-1 resmetirom data announced

Madrigal’s commercial team:

 

Madrigal’s commercial team is in constant pursuit of excellence in what we do and the way we show-up, every day. Conducting our business in an honest and transparent fashion is of prime importance to us. We have a “business owner” mentality as we feel the awesome responsibility to do right by the opportunity we have been given to bring a potentially revolutionary therapy to patients and their healthcare providers. It is essential for each one us on the commercial team to have deep and up-to-date knowledge of resmetirom program and developments in NASH as we prepare to answer the needs of the patients and physicians we hope to serve with approval and launch of resmetirom in the U.S.

 

Opportunity and Summary of Position:

 

We are searching for an inspiring, dynamic, and collaborative commercial leader with a successful track record of building and leading high-performing regional access teams and creating a culture of high engagement, accountability, and performance. The Executive Director of Regional Accounts will be responsible for the regional access strategy and approach, as well as the regional formulary access of resmetirom, and our future product portfolio in the US. The role will lead the functional build, resourcing, and readiness of our Regional Access team. Regional Access Director will have full accountability for the Regional Access team, including leadership of Regional Access Managers. This role will collaborate across the Commercialization teams including (and not limited to) Marketing, Medical Affairs, Insights and Analytics, and Key Account management team. This role is highly visible and critical to the success and future of Madrigal.

 

Position Responsibilities:

Develop and maintain deep understanding of NASH disease state, resmetirom clinical data and commercialization strategy; and while leading by example, assure the RAM team acquires and maintains deep knowledge of NASH disease state and resmetirom clinical data

Recruit high-caliber talent for RAM team in line with prioritized competencies

Identify and address lack-of-performance in the RAM team in a data-driven, timely and professional manner

Develop both short and long term strategic plans to optimize Resmetirom coverage using value propositions, HEOR and aligned MSL support

Demonstrate a leading from the front mentality while engaging directly with regional accounts in support of the RAM team

Work closely with local Sales and KAM leadership to ensure focus on opportunity accounts for pull-through while mitigating payer obstacles

Work with Marketing, Legal, Compliance, HEOR to ensure development of compliant, impactful, up to date payer customer facing materials

Clearly articulate the business plan and strategy for regional accounts to senior Madrigal leadership to gain trust and support

Prepare and disseminate quarterly updates on regional account performance as well as proposed tactics to ensure that tracked KPI’s are met and exceeded

Become a knowledge broker with internal stakeholders to grow the access acumen and understanding across Madrigal

Create an engaging, performance based culture that motivates the team to exceed expectation

Expect to spend ~80% of work time dedicated to leading and managing the Regional Access Team and ~20% involved in HQ matters during launch year

While leading by example, ensure that the RAM team operates with highest compliance and integrity standards

Qualifications and Skills

Bachelors degree

5-7 years of market access account management experience

Sales /Sales leadership/Access leadership preferred

Excellent executive presence and presentation skills

Deep customer relationships with regional payers

Solid launch experience within market access

Demonstrates exceptional leadership, management, and communication skills to inspire RAM team to achieve high levels of performance

Expert level knowledge of reimbursement and market access strategies

Experience working with all levels of management and consulting with key business stakeholders, with an ability to influence for greater outcomes

Possesses strong written and verbal communication skills

Excitement about the vision and mission of Madrigal

Compensation

An attractive compensation package will be offered to the successful candidate. It will include a competitive base salary and incentive bonus. A benefits package customary to the position will also be provided including 401k match, medical and dental.

Madrigal is an Equal Opportunity Employer and will judge all applicants based on their qualifications for the job, without regard to race, color, sex, religion, national origin, age, disability, sexual orientation, gender identity, protected veteran, disability status or any other characteristics protected by applicable federal, state or local law.

Unsolicited resumes from agencies should not be forwarded to Madrigal.

 

Madrigal will not be responsible for any fees arising from the use of resumes through this source. Madrigal will only pay a fee to agencies if a formal agreement between Madrigal and the agency has been established.

 

Proof of full vaccination against COVID-19 prior to the start date is required.